Wednesday, March 19, 2025
spot_img

HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2025 Financial Results

Highlights of the fiscal year include:

  • Revenue of $1.20 billion, an increase of 20% compared to $999.6 million in FY24.
  • Net income of $96.7 million, an increase of 74% compared to $55.7 million in FY24, with non-GAAP net income of $277.3 million, an increase of 42% compared to $195.5 million in FY24.
  • Net income per diluted share of $1.09, an increase of 70% compared to $0.64 in FY24, with non-GAAP net income per diluted share of $3.12, an increase of 39% compared to $2.25 in FY24.
  • Adjusted EBITDA of $471.8 million, an increase of 28% compared to $369.2 million in FY24.
  • 9.9 million HSAs, an increase of 14% compared to FY24.
  • Total HSA Assets of $32.1 billion, an increase of 27% compared to FY24.
  • 17.0 million Total Accounts, including both HSAs and complementary CDBs, an increase of 9% compared to FY24.
  • The Company completed its acquisition of the BenefitWallet HSA portfolio.
  • The Company repurchased 1.4 million shares of its common stock for $122.2 million.

Highlights of the fourth quarter include:

  • Revenue of $311.8 million, an increase of 19% compared to $262.4 million in Q4 FY24.
  • Net income of $26.4 million, the same as in Q4 FY24, with non-GAAP net income of $61.3 million, compared to $55.0 million in Q4 FY24.
  • Net income per diluted share of $0.30, the same as in Q4 FY24, with non-GAAP net income per diluted share of $0.69, compared to $0.63 in Q4 FY24.
  • Adjusted EBITDA of $107.8 million, an increase of 9% compared to $98.8 million in Q4 FY24.

DRAPER, Utah, March 18, 2025 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA”) custodian, today announced financial results for its fourth quarter and fiscal year ended January 31, 2025.

“Team Purple finished fiscal ‘25 in strong fashion, with record revenues and major strides in advancing our strategic initiatives, allowing us to provide our outlook for an even stronger fiscal ‘26,” said Scott Cutler, President and Chief Executive Officer of HealthEquity. “With a focus on Member First Secure Mobile Experiences, we are executing against our 3Ds strategy to Deepen partnerships, Deliver remarkable experiences, and Drive member outcomes for our Clients, Network Partners, and members. We added a record one million new HSAs from sales this year and helped our nearly 10 million HSA members grow their HSA balances to over $32 billion.”

Fiscal year financial results

Revenue for the fiscal year ended January 31, 2025 was $1.20 billion, an increase of 20% compared to $999.6 million for the fiscal year ended January 31, 2024. Revenue this year included: service revenue of $478.3 million, custodial revenue of $545.4 million, and interchange revenue of $176.0 million.

HealthEquity reported net income of $96.7 million, or $1.09 per diluted share, and non-GAAP net income of $277.3 million, or $3.12 per diluted share, for the fiscal year ended January 31, 2025. The Company reported net income of $55.7 million, or $0.64 per diluted share, and non-GAAP net income of $195.5 million, or $2.25 per diluted share, for the fiscal year ended January 31, 2024.

Adjusted EBITDA was $471.8 million for the fiscal year ended January 31, 2025, an increase of 28% compared to $369.2 million for the fiscal year ended January 31, 2024. Adjusted EBITDA was 39% of revenue, compared to 37% for the fiscal year ended January 31, 2024.

As of January 31, 2025, HealthEquity had $295.9 million of cash and cash equivalents and $1.06 billion of outstanding debt, net of issuance costs. This compares to $404.0 million in cash and cash equivalents and $875.0 million of outstanding debt as of January 31, 2024.

Fourth quarter financial results

Revenue for the fourth quarter ended January 31, 2025 was $311.8 million, an increase of 19% compared to $262.4 million for the fourth quarter ended January 31, 2024. Revenue this quarter included: service revenue of $124.2 million, custodial revenue of $144.1 million, and interchange revenue of $43.5 million.

HealthEquity reported net income of $26.4 million, or $0.30 per diluted share, and non-GAAP net income of $61.3 million, or $0.69 per diluted share, for the fourth quarter ended January 31, 2025. The Company reported net income of $26.4 million, or $0.30 per diluted share, and non-GAAP net income of $55.0 million, or $0.63 per diluted share, for the fourth quarter ended January 31, 2024.

Adjusted EBITDA was $107.8 million for the fourth quarter ended January 31, 2025, an increase of 9% compared to $98.8 million for the fourth quarter ended January 31, 2024. Adjusted EBITDA was 35% of revenue, compared to 38% for the fourth quarter ended January 31, 2024.

Account and asset metrics

HSAs as of January 31, 2025 were 9.9 million, an increase of 14% year over year, including 753,000 HSAs with investments, an increase of 23% year over year. Total Accounts as of January 31, 2025 were 17.0 million, including 7.1 million other consumer-directed benefits (“CDBs”).

Total HSA Assets as of January 31, 2025 were $32.1 billion, an increase of 27% year over year. Total HSA Assets included $17.4 billion of HSA cash and $14.7 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.9 billion as of January 31, 2025.

BenefitWallet HSA portfolio acquisition

In the first half of fiscal 2025, we acquired the BenefitWallet HSA portfolio, comprised of approximately 616,000 HSAs plus other accounts and $2.7 billion of HSA Assets, from Conduent Business Services, LLC for a purchase price of $425.0 million. We paid the purchase price using $225.0 million of borrowings under our revolving credit facility, with the remainder paid using cash on hand.

Stock repurchase program

The Company repurchased 1.4 million shares of its common stock for $122.2 million during the fiscal year ended January 31, 2025. As of January 31, 2025, $177.8 million of common stock remained authorized for repurchase under the Company’s stock repurchase program.

Business outlook

For the fiscal year ending January 31, 2026, management expects revenues of $1.280 billion to $1.305 billion. Its outlook for net income is between $164 million and $179 million, resulting in net income of $1.85 to $2.01 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $318 million and $333 million, resulting in non-GAAP net income per diluted share of $3.57 to $3.74 (based on an estimated 89 million weighted-average shares outstanding). Management expects Adjusted EBITDA of $525 million to $545 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, March 18, 2025 to discuss the fiscal 2025 fourth quarter and year-end results. The conference call will be accessible by dialing 1-844-481-2556, or 1-412-317-0560 for international callers, and referencing conference ID “HealthEquity.” A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

  • Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
  • Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
  • Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our vision of saving and improving the lives of healthcare consumers. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

  • our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
  • our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
  • our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
  • risks relating to our recent CEO transition;
  • the impact of increased fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;
  • our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
  • the significant competition we face and may face in the future, including from those with greater resources than us;
  • our reliance on the availability and performance of our technology and communications systems;
  • recent and potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
  • the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
  • potential regulatory changes and changes in the enforcement environment under the new U.S. administration;
  • our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
  • our reliance on partners and third-party vendors for distribution and important services;
  • our ability to develop and implement updated features for our technology platforms and communications systems; and
  • our reliance on our management team and key team members.

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2025. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact
Richard Putnam
801-727-1000
[email protected]


HealthEquity, Inc. and subsidiaries

Consolidated balance sheets (unaudited)

(in thousands, except par value)   January 31, 2025       January 31, 2024  
Assets              
Current assets              
Cash and cash equivalents $         295,948     $         403,979  
Accounts receivable, net of allowance for doubtful accounts of $2,070 and $3,947 as of January 31, 2025 and 2024, respectively           118,006               104,893  
Other current assets           63,795               48,564  
Total current assets           477,749               557,436  
Property and equipment, net           3,239               6,013  
Operating lease right-of-use assets           43,185               48,380  
Intangible assets, net           1,204,658               835,948  
Goodwill           1,648,145               1,648,145  
Other assets           71,574               67,868  
Total assets $         3,448,550     $         3,163,790  
Liabilities and stockholders’ equity      
Current liabilities      
Accounts payable $         14,361     $         12,041  
Accrued compensation           69,330               49,608  
Accrued liabilities           62,631               46,038  
Operating lease liabilities           10,001               9,404  
Total current liabilities           156,323               117,091  
Long-term liabilities      
Long-term debt, net of issuance costs           1,056,301               874,972  
Operating lease liabilities, non-current           42,219               48,766  
Other long-term liabilities           22,962               19,270  
Deferred tax liability           55,834               68,670  
Total long-term liabilities           1,177,316               1,011,678  
Total liabilities           1,333,639               1,128,769  
Commitments and contingencies      
Stockholders’ equity      
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of January 31, 2025 and 2024           —               —  
Common stock, $0.0001 par value, 900,000 shares authorized, 86,536 and 86,127 shares issued and outstanding as of January 31, 2025 and 2024, respectively           9               9  
Additional paid-in capital           1,905,628               1,829,384  
Accumulated earnings           209,274               205,628  
Total stockholders’ equity           2,114,911               2,035,021  
Total liabilities and stockholders’ equity $         3,448,550     $         3,163,790  


HealthEquity, Inc. and subsidiaries

Consolidated statements of operations and comprehensive income (unaudited)

  Three months ended January 31,     Year ended January 31,  
(in thousands, except per share data)   2025       2024       2025       2024  
Revenue              
Service revenue $         124,209     $         118,575     $         478,317     $         455,690  
Custodial revenue           144,133               105,433               545,414               386,594  
Interchange revenue           43,475               38,379               176,043               157,303  
Total revenue           311,817               262,387               1,199,774               999,587  
Cost of revenue              
Service costs           105,466               83,859               351,588               317,357  
Custodial costs           10,269               8,398               39,675               32,502  
Interchange costs           7,039               6,810               31,252               27,091  
Total cost of revenue           122,774               99,067               422,515               376,950  
Gross profit           189,043               163,320               777,259               622,637  
Operating expenses              
Sales and marketing           23,084               20,559               90,739               79,273  
Technology and development           64,654               55,238               239,513               218,811  
General and administrative           29,975               23,140               132,260               103,656  
Amortization of acquired intangible assets           27,002               23,218               111,878               92,763  
Merger integration           2,178               2,278               40,535               10,435  
Total operating expenses           146,893               124,433               614,925               504,938  
Income from operations           42,150               38,887               162,334               117,699  
Other expense              
Interest expense           (15,257 )             (13,641 )             (60,634 )             (55,455 )
Other income, net           3,068               4,471               14,334               12,796  
Total other expense           (12,189 )             (9,170 )             (46,300 )             (42,659 )
Income before income taxes           29,961               29,717               116,034               75,040  
Income tax provision           3,596               3,353               19,331               19,328  
Net income and comprehensive income $         26,365     $         26,364     $         96,703     $         55,712  
Net income per share:              
Basic $         0.30     $         0.31     $         1.11     $         0.65  
Diluted $         0.30     $         0.30     $         1.09     $         0.64  
Weighted-average number of shares used in computing net income per share:              
Basic           86,677               85,975               86,870               85,564  
Diluted           88,614               87,435               88,828               86,957  


HealthEquity, Inc. and subsidiaries

Consolidated statements of cash flows (unaudited)

  Year ended January 31,  
(in thousands)   2025       2024  
Cash flows from operating activities:      
Net income $         96,703     $         55,712  
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization           162,451               153,078  
Stock-based compensation           96,425               77,151  
Amortization of debt issuance costs           2,067               2,852  
Loss on extinguishment of debt           1,576               1,157  
Deferred taxes           (12,836 )             (13,995 )
Changes in operating assets and liabilities:      
Accounts receivable           (13,113 )             (8,058 )
Other assets           (11,790 )             (32,790 )
Operating lease right-of-use assets           6,664               10,190  
Accrued compensation           17,758               2,951  
Accounts payable, accrued liabilities, and other current liabilities           8,888               (204 )
Operating lease liabilities, non-current           (7,779 )             (11,780 )
Other long-term liabilities           (7,158 )             6,562  
Net cash provided by operating activities           339,856               242,826  
Cash flows from investing activities:      
Purchases of software and capitalized software development costs           (51,129 )             (41,123 )
Acquisitions of HSA portfolios           (452,241 )             (3,257 )
Purchases of property and equipment           (2,084 )             (1,694 )
Net cash used in investing activities           (505,454 )             (46,074 )
Cash flows from financing activities:      
Principal payments on long-term debt           (561,875 )             (54,375 )
Proceeds from long-term debt           736,875               —  
Payment of debt issuance costs           (3,748 )             —  
Repurchases of common stock           (121,493 )             —  
Settlement of client-held funds obligation, net           (1,620 )             865  
Proceeds from exercise of common stock options           9,428               6,471  
Net cash provided by (used in) financing activities           57,567               (47,039 )
Increase (decrease) in cash and cash equivalents           (108,031 )             149,713  
Beginning cash and cash equivalents           403,979               254,266  
Ending cash and cash equivalents $         295,948     $         403,979  


HealthEquity, Inc. and subsidiaries

Consolidated statements of cash flows (unaudited) (continued)

  Year ended January 31,  
(in thousands)   2025       2024  
Supplemental cash flow data:      
Interest expense paid in cash $         58,587     $         49,560  
Income tax payments, net           26,069               35,352  
Supplemental disclosures of non-cash investing and financing activities:      
Non-cash purchase consideration related to acquisitions of HSA portfolios           20,325               —  
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation           5,971               3,145  
Repurchases of common stock included in accrued liabilities           754               —  
Purchases of property and equipment included in accounts payable or accrued liabilities           45               263  
Exercise of common stock options receivable           10               429  


Stock-based compensation expense (unaudited)

Total stock-based compensation expense included in the consolidated statements of operations and comprehensive income is as follows:

  Three months ended January 31,     Year ended January 31,  
(in thousands)   2025       2024       2025       2024  
Cost of revenue $         3,745     $         4,120     $         14,955     $         16,462  
Sales and marketing           3,750               3,419               15,623               13,182  
Technology and development           6,255               5,793               25,002               20,891  
General and administrative           7,958               3,880               40,845               26,616  
Total stock-based compensation expense $         21,708     $         17,212     $         96,425     $         77,151  


Total Accounts (unaudited)

(in thousands, except percentages) January 31, 2025     January 31, 2024     % Change    
HSAs         9,889             8,692             14   %
New HSAs from sales – Quarter-to-date 471     497     (5 ) %
New HSAs from sales – Year-to-date         1,040             949             10   %
New HSAs from acquisitions – Year-to-date         616             —     *
HSAs with investments         753             610             23   %
CDBs         7,144             7,006             2   %
Total Accounts         17,033             15,698             9   %
Average Total Accounts – Quarter-to-date         16,677             15,318             9   %
Average Total Accounts – Year-to-date         16,302             15,105             8   %

*  Not meaningful
 


HSA assets (unaudited)

(in millions, except percentages) January 31, 2025     January 31, 2024     % Change    
HSA cash $         17,435     $         15,006             16   %
HSA investments           14,676               10,208             44   %
Total HSA Assets           32,111               25,214             27   %
Average daily HSA cash – Quarter-to-date           16,634               14,210             17   %
Average daily HSA cash – Year-to-date           16,206               14,071             15   %

The following table summarizes the amount of HSA cash held by our Depository Partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of January 31, 2025:

Year ending January 31, (in billions, except percentages) HSA cash expected to reprice     Average annualized yield    
2026 $         2.3             2.5   %
2027           4.1             1.9   %
2028           2.1             4.0   %
2029           1.5             3.6   %
Thereafter           6.6             4.4   %
Total (1) $         16.6             3.4   %

(1) Excludes $0.8 billion of HSA cash held in floating-rate contracts as of January 31, 2025.
   


Client-held funds (unaudited)

(in millions, except percentages)   January 31, 2025       January 31, 2024     % Change    
Client-held funds $         896     $         842             6   %
Average daily Client-held funds – Quarter-to-date           798               791             1   %
Average daily Client-held funds – Year-to-date   817       845     (3 ) %

Net income reconciliation to Adjusted EBITDA (unaudited)

  Three months ended January 31,     Year ended January 31,  
(in thousands)   2025       2024       2025       2024  
Net income $         26,365     $         26,364     $         96,703     $         55,712  
Interest income           (3,033 )             (4,343 )             (13,914 )             (12,138 )
Interest expense           15,257               13,641               60,634               55,455  
Income tax provision           3,596               3,353               19,331               19,328  
Depreciation and amortization           12,180               14,693               50,573               60,315  
Amortization of acquired intangible assets           27,002               23,218               111,878               92,763  
Stock-based compensation expense           21,708               17,212               96,425               77,151  
Merger integration expenses           2,178               2,278               40,535               10,435  
Amortization of incremental costs to obtain a contract           1,730               1,402               6,745               5,435  
Costs associated with unused office space           836               927               3,244               4,179  
Other           (35 )             84               (403 )             538  
Adjusted EBITDA $         107,784     $         98,829     $         471,751     $         369,173  


Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)

  Outlook for the year ending  
(in millions) January 31, 2026  
Net income $164 – 179  
Interest income (9 )
Interest expense 53  
Income tax provision 55 – 60  
Depreciation and amortization 49  
Amortization of acquired intangible assets 108  
Stock-based compensation expense 85  
Merger integration expenses 9  
Amortization of incremental costs to obtain a contract 8  
Costs associated with unused office space 3  
Adjusted EBITDA $525 – 545  


Reconciliation of net income to non-GAAP net income (unaudited)

  Three months ended January 31,     Year ended January 31,  
(in thousands, except per share data)   2025       2024       2025       2024  
Net income $         26,365     $         26,364     $         96,703     $         55,712  
Income tax provision           3,596               3,353               19,331               19,328  
Income before income taxes – GAAP           29,961               29,717               116,034               75,040  
Non-GAAP adjustments:              
Amortization of acquired intangible assets           27,002               23,218               111,878               92,763  
Stock-based compensation expense           21,708               17,212               96,425               77,151  
Merger integration expenses           2,178               2,278               40,535               10,435  
Costs associated with unused office space           836               927               3,244               4,179  
Loss on extinguishment of debt           —               —               1,576               1,157  
Total adjustments to income before income taxes – GAAP           51,724               43,635               253,658               185,685  
Income before income taxes – Non-GAAP           81,685               73,352               369,692               260,725  
Income tax provision – Non-GAAP (1)           20,421               18,337               92,423               65,180  
Non-GAAP net income           61,264               55,015               277,269               195,545  
               
Diluted weighted-average shares           88,614               87,435               88,828               86,957  
GAAP net income per diluted share $         0.30     $         0.30     $         1.09     $         0.64  
Non-GAAP net income per diluted share $         0.69     $         0.63     $         3.12     $         2.25  

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
   


Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)

  Outlook for the year ending  
(in millions, except per share data) January 31, 2026  
Net income $164 – 179  
Income tax provision 55 – 60  
Income before income taxes – GAAP 219 – 239  
Non-GAAP adjustments:    
Amortization of acquired intangible assets 108  
Stock-based compensation expense 85  
Merger integration expenses 9  
Costs associated with unused office space 3  
Total adjustments to income before income taxes – GAAP 205  
Income before income taxes – Non-GAAP 424 – 444  
Income tax provision – Non-GAAP (1) 106 – 111  
Non-GAAP net income $318 – 333  
     
Diluted weighted-average shares 89  
GAAP net income per diluted share (2) $1.85 – 2.01  
Non-GAAP net income per diluted share (2) $3.57 – 3.74  

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
(2) GAAP and Non-GAAP net income per diluted share may not calculate due to rounding.
   


Certain terms

Term   Definition
HSA   A financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDB   Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.
HSA member   Consumers with HSAs that we serve.
Total HSA Assets   HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members’ investments held by our custodial investment fund partner.
Client   Our employer clients.
Total Accounts   The sum of HSAs and CDBs on our platforms.
Client-held funds   Deposits held on behalf of our Clients to facilitate administration of our CDBs.
Network Partner   Our health plan partners, benefits administrators, and retirement plan recordkeepers.
Adjusted EBITDA   Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
Non-GAAP net income   Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
Non-GAAP net income per diluted share   Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Powered by SlickText.com

Hot this week

Dovre Group Plc: Managers’ Transactions – Koskelo Ilari

Dovre Group Plc                   Managers’ Transactions               March 19, 2025, at 3:45 pm...

Duty of disclosure: Transactions in shares in Ringkjøbing Landbobank A/S

Nasdaq CopenhagenLondon Stock ExchangeEuronext DublinDanish Financial Supervisory AuthorityOther Stakeholders...

Net Asset Value(s)

Octopus AIM VCT 2 plc Net Asset Value...

Net Asset Value(s)

Octopus AIM VCT plc Net Asset Value ...

Topics

Dovre Group Plc: Managers’ Transactions – Koskelo Ilari

Dovre Group Plc                   Managers’ Transactions               March 19, 2025, at 3:45 pm...

Duty of disclosure: Transactions in shares in Ringkjøbing Landbobank A/S

Nasdaq CopenhagenLondon Stock ExchangeEuronext DublinDanish Financial Supervisory AuthorityOther Stakeholders...

Net Asset Value(s)

Octopus AIM VCT 2 plc Net Asset Value...

Net Asset Value(s)

Octopus AIM VCT plc Net Asset Value ...
spot_img

Related Articles

Popular Categories

spot_img